IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1).
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 14, 2025 | -$0.31 | -$0.13 | Beat |
| Aug 14, 2025 | -$0.35 | -$0.40 | Miss |
| May 14, 2025 | -$0.45 | -$0.34 | Beat |
| Mar 25, 2025 | -$0.38 | -$0.48 | Miss |
| Nov 12, 2024 | -$0.29 | -$0.36 | Miss |
| Aug 13, 2024 | -$0.34 | -$0.31 | Beat |